scholarly journals Low-dose ritonavir-boosted darunavir in virologically suppressed HIV-1-infected adults: an open-label trial (ANRS 165 Darulight)

2018 ◽  
Vol 73 (8) ◽  
pp. 2129-2136 ◽  
Author(s):  
Jean-Michel Molina ◽  
Sebastien Gallien ◽  
Marie-Laure Chaix ◽  
El Mountacer El Abbassi ◽  
Isabelle Madelaine ◽  
...  
Keyword(s):  
Low Dose ◽  
Open Label ◽  
Open Label Trial ◽  
Hiv 1

An Open Label Trial of Low-Dose Naltrexone (LDN) for Symptomatic Mesenteric Panniculitis Presidential Poster

2015 ◽  
Vol 110 ◽  
pp. S434-S435
Author(s):  
Constantine Melitas ◽  
Grigory Roginsky ◽  
Aimee Alexoff ◽  
Eli D. Ehrenpreis
Keyword(s):  
Low Dose ◽  
Mesenteric Panniculitis ◽  
Open Label ◽  
Open Label Trial ◽  
Low Dose Naltrexone

Efficacy of Low-Dose Alteplase for Treatment of Hemodialysis Catheter Occlusions

2005 ◽  
Vol 6 (2) ◽  
pp. 76-82 ◽  
Author(s):  
J. Haymond ◽  
K. Shalansky ◽  
J. Jastrzebski
Keyword(s):  
Cost Reduction ◽  
Primary Outcome ◽  
Low Dose ◽  
Financial Analysis ◽  
Blood Flow Rate ◽  
Venous Catheter ◽  
Open Label ◽  
Hemodialysis Catheter ◽  
Catheter Patency ◽  
Open Label Trial

Background Traditionally, alteplase 2 mg/lumen doses have been used to treat central venous catheter (CVC) occlusions. On January 20, 2004, our hemodialysis (HD) unit implemented a new protocol to utilize alteplase 1 mg/lumen doses for catheter occlusion. Objectives The objectives were to 1) assess the efficacy of low-dose alteplase in restoring HD catheter patency; 2) determine the duration of CVC patency as determined by need for further alteplase doses, or radiological or surgical line interventions; and 3) evaluate the financial implications of the new protocol. Methods The study was a prospective, open-label trial of 50 consecutive HD patients with permanent, tunnelled CVC lines. A treatment course consisted of 1 or 2 doses of alteplase instilled for 60 minutes then aspirated or as an overnight (48–72 hour) dwell until the next HD. The patient's first alteplase dose following implementation of the new protocol was evaluated. Patients were followed for two months to record need for further alteplase treatment courses, and four months to document radiological or surgical line interventions. The primary outcome was to assess successful restoration of catheter patency defined as the ability of alteplase to restore or maintain HD blood flow rate at or above 300 mL/minute. A financial analysis compared alteplase costs for 11 months prior to and after implementation of the new protocol. Results Alteplase 1 mg/lumen doses restored catheter patency in 72% of HD patients with one dose, increasing to 83% with a second dose. Sixty-two percent of patients required a subsequent alteplase course with a median time to next treatment of 14 days and a median of 2 courses/patient. Radiological interventions were ordered in 38% of patients resulting in 8 lines replacements and 7 line strippings. Financial savings with the new low-dose protocol were ~CDN$22,000. Conclusion Low dose alteplase 1 mg/lumen successfully treated occlusion of permanent hemodialysis catheters, with a resulting cost reduction.

scholarly journals Very Low-Dose Risperidone in First-Episode Psychosis: A Safe and Effective Way to Initiate Treatment

2011 ◽  
Vol 2011 ◽  
pp. 1-10 ◽  
Author(s):  
Patrick D. McGorry ◽  
John Cocks ◽  
Paddy Power ◽  
Peter Burnett ◽  
Susy Harrigan ◽  
...  
Keyword(s):  
Low Dose ◽  
Chronic Schizophrenia ◽  
First Episode Psychosis ◽  
First Episode ◽  
Psychotic Episode ◽  
Open Label ◽  
First Psychotic Episode ◽  
Episode Psychosis ◽  
Open Label Trial ◽  
Risperidone Treatment

Patients experiencing a first psychotic episode have high rates of extrapyramidal symptoms (EPSs) when treated with the doses of neuroleptics used in multiepisode or chronic schizophrenia. There is some evidence that lower doses may be equally, if not more, effective but less toxic in this population. Here, we report the results of a biphasic open label trial designed to assess the efficacy, safety, and tolerability of low-dose (2–4 mg/day) risperidone treatment in a group of 96 first-episode nonaffective psychosis patients. At the end of the trial, 62% of patients met the response criteria although approximately 80% had achieved a response at some time during the study. Reports of EPS remained low, and there were no dystonic reactions. We conclude that even at a dose of 2 mg/day, risperidone was highly effective in reducing acute symptomatology in a real world sample of young first-episode psychosis patients.

scholarly journals MP72-20 IMPACT OF TADALAFIL ON ADVERSE EVENTS AFTER LOW DOSE RATE BRACHYTHERAPY FOR PROSTATE CANCER- A MULTI CENTER RANDOMIZED OPEN LABEL TRIAL

2019 ◽  
Vol 201 (Supplement 4) ◽  
Author(s):  
Tomohiko Oguchi* ◽  
Tomonori Minagawa ◽  
Ayumu Fukasawa ◽  
Kazuyoshi Iijima ◽  
Keiichiro Koiwai ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Adverse Events ◽  
Dose Rate ◽  
Low Dose ◽  
Open Label ◽  
Low Dose Rate ◽  
Open Label Trial ◽  
Low Dose Rate Brachytherapy

scholarly journals Switch from Enfuvirtide to Raltegravir in Virologically Suppressed Multidrug‐Resistant HIV‐1–Infected Patients: A Randomized Open‐Label Trial

2009 ◽  
Vol 49 (8) ◽  
pp. 1259-1267 ◽  
Author(s):  
Nathalie De Castro ◽  
Joséphine Braun ◽  
Isabelle Charreau ◽  
Gilles Pialoux ◽  
Laurent Cotte ◽  
...  
Keyword(s):  
Multidrug Resistant ◽  
Open Label ◽  
Open Label Trial ◽  
Hiv 1
Sign in / Sign up

Export Citation Format

Share Document